Phenylbutyric acid (PBA) has been reported as a dual inhibitor of pyruvate dehydrogenase kinases (PDKs) and histone deacetylases (HDACs), exhibiting anticancer effects. However, the low membrane permeability and poor cellular uptake limit its access to the target organelle, resulting in weak potencies against the intended targets. Herein, we report the design and identification of a novel 4-CF<sub>3</sub>-phenyl triphenylphosphonium-based PBA conjugate (<b>53</b>) with improved <i>in vitro</i> and <i>in vivo</i> anticancer activities. Compound <b>53</b> exhibited an IC<sub>50</sub> value of 2.22 μM against A375 cells, outperforming the parent drug PBA by about 4000-fold. In the A375 cell-derived xenograft mouse model, <b>53</b> reduced the tumor growth by 76% at a dose of 40 mg/kg, while PBA only reduced the tumor growth by 10% at a dose of 80 mg/kg. On the basis of these results, <b>53</b> may be considered for further preclinical evaluations for cancer therapy.